Other Species / Isoforms
  UBXN2B (human)      LTP 

LTP (Low Throughput Papers) : The number of records in which this modification site was determined using methods other than discovery mass spectrometry.

  HTP 

HTP (High Throughput Papers): The number of records in which this modification site was assigned using ONLY proteomic discovery mass spectrometry.

 
S17-p
GEQERRSsGPRPPsA
0 1
UBXN2B (human) GEQERRSsGPRPPsA S17-p
UBXN2B (mouse) EEQERGSSRPRPPSA S17
UBXN2B (rat) EEQERRSSRPRPPSA S17
S23-p
SsGPRPPsARDLQLA
0 4
UBXN2B (human) SsGPRPPsARDLQLA S23-p
UBXN2B (mouse) SSRPRPPSARDLQLA S23
UBXN2B (rat) SSRPRPPSARDLQLA S23
Y35-p
QLALAELyEDEVkCK
0 2
UBXN2B (human) QLALAELyEDEVkCK Y35-p
UBXN2B (mouse) QLALAELYEDEMKCK Y35
UBXN2B (rat) QLALAELYEDEMKCK Y35
K40-ub
ELyEDEVkCKSSKsN
0 1
UBXN2B (human) ELyEDEVkCKSSKsN K40-ub
UBXN2B (mouse) ELYEDEMKCKSSKPD K40
UBXN2B (rat) ELYEDEMKCKSSKPD K40
S46-p
VkCKSSKsNRPkATV
0 1
UBXN2B (human) VkCKSSKsNRPkATV S46-p
UBXN2B (mouse) MKCKSSKPDRStPAT P46
UBXN2B (rat) MKCKSSKPDRSTATA P46
K50
SSKsNRPKATVFksP
0 1
UBXN2B (human) SSKsNRPKATVFksP K50
UBXN2B (mouse) SSKPDRStPATCRsP T50-p
UBXN2B (rat) SSKPDRSTATAFKSP T50
K50-ub
SSKsNRPkATVFksP
0 1
UBXN2B (human) SSKsNRPkATVFksP K50-ub
UBXN2B (mouse) SSKPDRSTPATCRsP T50
UBXN2B (rat) SSKPDRSTATAFKSP T50
K55-ub
RPkATVFksPRtPPQ
0 1
UBXN2B (human) RPkATVFksPRtPPQ K55-ub
UBXN2B (mouse) RStPATCRsPRtPPH R55
UBXN2B (rat) RSTATAFKSPRTPPL K55
K55-m1
RPkATVFksPRtPPQ
0 1
UBXN2B (human) RPkATVFksPRtPPQ K55-m1
UBXN2B (mouse) RStPATCRsPRtPPH R55
UBXN2B (rat) RSTATAFKSPRTPPL K55
S56-p
PkATVFksPRtPPQR
Upstream
Downstream
1 10
Effects on Modified Protein
  • intracellular localization
  • molecular association, regulation
Kinase, in vitro:
  • CDK1 (human)
UBXN2B (human) PkATVFksPRtPPQR S56-p
UBXN2B (mouse) StPATCRsPRtPPHR S56-p
UBXN2B (rat) STATAFKSPRTPPLR S56
T59-p
TVFksPRtPPQRFys
Upstream
Downstream
1 15
Effects on Modified Protein
  • intracellular localization
  • molecular association, regulation
Kinase, in vitro:
  • CDK1 (human)
Treatment
  • ischemia
UBXN2B (human) TVFksPRtPPQRFys T59-p
UBXN2B (mouse) ATCRsPRtPPHRLYs T59-p
UBXN2B (rat) TAFKSPRTPPLRLYS T59
Y65-p
RtPPQRFyssEHEYS
0 1
UBXN2B (human) RtPPQRFyssEHEYS Y65-p
UBXN2B (mouse) RtPPHRLYsGDHKYD Y65
UBXN2B (rat) RTPPLRLYSGDQEYG Y65
S66-p
tPPQRFyssEHEYSG
Upstream
0 26
Treatment
  • ischemia
UBXN2B (human) tPPQRFyssEHEYSG S66-p
UBXN2B (mouse) tPPHRLYsGDHKYDG S66-p
UBXN2B (rat) TPPLRLYSGDQEYGG S66
S67-p
PPQRFyssEHEYSGL
0 2
UBXN2B (human) PPQRFyssEHEYSGL S67-p
UBXN2B (mouse) PPHRLYsGDHKYDGL G67
UBXN2B (rat) PPLRLYSGDQEYGGL G67
K90
KIVNELFKEAREHGA
0 1
UBXN2B (human) KIVNELFKEAREHGA K90
UBXN2B (mouse) KIVNELFKEAREHGA K90
UBXN2B (rat) KIVNELFkEAREHGA K90-ac
K90-ub
KIVNELFkEAREHGA
0 1
UBXN2B (human) KIVNELFkEAREHGA K90-ub
UBXN2B (mouse) KIVNELFKEAREHGA K90
UBXN2B (rat) KIVNELFKEAREHGA K90
T104-p
AVPLNEAtRAsGDDK
0 1
UBXN2B (human) AVPLNEAtRAsGDDK T104-p
UBXN2B (mouse) AVPLNEATRSSREDK T104
UBXN2B (rat) AVPLNEATRSSSDDK T104
S107-p
LNEAtRAsGDDKsks
0 1
UBXN2B (human) LNEAtRAsGDDKsks S107-p
UBXN2B (mouse) LNEATRSSREDKTKS S107
UBXN2B (rat) LNEATRSSSDDKAKS S107
S112-p
RAsGDDKsksFTGGG
0 1
UBXN2B (human) RAsGDDKsksFTGGG S112-p
UBXN2B (mouse) RSSREDKTKSFTGGG T112
UBXN2B (rat) RSSSDDKAKSFTGGG A112
K113-ub
AsGDDKsksFTGGGY
0 1
UBXN2B (human) AsGDDKsksFTGGGY K113-ub
UBXN2B (mouse) SSREDKTKSFTGGGY K113
UBXN2B (rat) SSSDDKAKSFTGGGY K113
S114-p
sGDDKsksFTGGGYR
0 1
UBXN2B (human) sGDDKsksFTGGGYR S114-p
UBXN2B (mouse) SREDKTKSFTGGGYR S114
UBXN2B (rat) SSDDKAKSFTGGGYR S114
S125-p
GGYRLGSsFCkRSEY
0 2
UBXN2B (human) GGYRLGSsFCkRSEY S125-p
UBXN2B (mouse) GGYRLGNSFYKRSEY S125
UBXN2B (rat) GGYRLGSSFYKRSEY S125
K128-ub
RLGSsFCkRSEYIYG
0 1
UBXN2B (human) RLGSsFCkRSEYIYG K128-ub
UBXN2B (mouse) RLGNSFYKRSEYIYG K128
UBXN2B (rat) RLGSSFYKRSEYIYG K128
K176-ub
AQFLESVkRGEIPLE
0 3
UBXN2B (human) AQFLESVkRGEIPLE K176-ub
UBXN2B (mouse) AQFLESVKRGETPLE K176
UBXN2B (rat) AQFLESVKRGEIPLE K176
K207-ub
HQDQEYIkPRLRFkA
0 2
UBXN2B (human) HQDQEYIkPRLRFkA K207-ub
UBXN2B (mouse) HQDQEYIKPRLRFKA K207
UBXN2B (rat) HQDQEYIKPRLRFKA K207
K213-ub
IkPRLRFkAFsGEGQ
0 2
UBXN2B (human) IkPRLRFkAFsGEGQ K213-ub
UBXN2B (mouse) IKPRLRFKAFsGEGQ K213
UBXN2B (rat) IKPRLRFKAFSGEGQ K213
S216-p
RLRFkAFsGEGQkLG
Upstream
0 6
Treatment
  • ischemia
UBXN2B (human) RLRFkAFsGEGQkLG S216-p
UBXN2B (mouse) RLRFKAFsGEGQKLG S216-p
UBXN2B (rat) RLRFKAFSGEGQKLG S216
K221-ub
AFsGEGQkLGSLtPE
0 1
UBXN2B (human) AFsGEGQkLGSLtPE K221-ub
UBXN2B (mouse) AFsGEGQKLGSLTPE K221
UBXN2B (rat) AFSGEGQKLGSLTPE K221
T226-p
GQkLGSLtPEIVstP
0 2
UBXN2B (human) GQkLGSLtPEIVstP T226-p
UBXN2B (mouse) GQKLGSLTPEIVsTP T226
UBXN2B (rat) GQKLGSLTPEIVSTP T226
S231-p
SLtPEIVstPssPEE
0 7
UBXN2B (human) SLtPEIVstPssPEE S231-p
UBXN2B (mouse) SLTPEIVsTPssPEE S231-p
UBXN2B (rat) SLTPEIVSTPssPEE S231
T232-p
LtPEIVstPssPEEE
0 2
UBXN2B (human) LtPEIVstPssPEEE T232-p
UBXN2B (mouse) LTPEIVsTPssPEEE T232
UBXN2B (rat) LTPEIVSTPssPEEE T232
S234-p
PEIVstPssPEEEDK
0 10
UBXN2B (human) PEIVstPssPEEEDK S234-p
UBXN2B (mouse) PEIVsTPssPEEEDK S234-p
UBXN2B (rat) PEIVSTPssPEEEDK S234-p
S235-p
EIVstPssPEEEDKS
Upstream
0 16
Treatment
  • vemurafenib
UBXN2B (human) EIVstPssPEEEDKS S235-p
UBXN2B (mouse) EIVsTPssPEEEDKS S235-p
UBXN2B (rat) EIVSTPssPEEEDKS S235-p